When the government announces a tender for a vaccine against cervical cancer, MSD Pharma is expected to participate.

cervical cancer

CERVAVAC, an in-country vaccine developed by The Serum Institute to prevent cervical cancer, was introduced last month. In a recent letter to the Health Ministry, Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII), stated that the company’s first indigenous HPV vaccination will be sold on the private market for Rs 2,000 per dose. CERVAVAC will be offered in glass vials with two doses.

In order to obtain the HPV vaccine against cervical cancer for immunization of girls between the ages of 9 and 14, the Union Health Ministry is likely to launch a global tender in April. MSD Pharmaceuticals is eager to participate. MSD Pharmaceuticals Private Limited, a wholly-owned subsidiary of Merck Sharp and Dohme (known as Merck and Co Inc in the US and Canada), sells its HPV vaccine Gardasil 4 (quadrivalent vaccine) in India. It is currently priced at Rs 3,927 per dose.

The company launched its first gender-neutral HPV vaccine, Gardasil 9, in the country in 2021. The nine-valent human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52 and 58 ) vaccine is currently priced in India at Rs 10,850 per dose. The company responded to a query from PTI by saying that because HPV affects people of both sexes, the introduction of the advanced Gardasil 9 vaccine “demonstrates our commitment to bringing a gender-neutral HPV vaccine to our country that addresses certain HPV related diseases among Indian girls, women, and boys.” MSD will also continue to support preventive healthcare in India, the company added.

The universal immunization program’s HPV vaccine against cervical cancer will start to be phased-in from June, according to the Union Health Ministry. It is expected to announce a global HPV tender in April for the purchase of 16.02 crore doses by 2026. If the Indian government issued a global tender, we would be eager to work on the immunization campaign. Additionally, we engage with multiple state governments in other important areas like oncology and maternity health, and we can do the same when it comes to providing HPV vaccines as part of larger roll-out plans “In response to a query, the business stated.

According to MSD, there is currently less than 1% HPV vaccination uptake in the target group, making India a crucial market for the cervical cancer vaccine. HPV vaccine awareness is definitely urgently needed in India. “For Indian women aged 9 to 45, Gardasil 4 has been approved. It indicates that MSD is making efforts to safeguard the 300 million or more women in India who need protection from malignancies linked to HPV. The entire public is being educated by the government extensively on cervical cancer prevention, it was stated. CERVAVAC, an in-country vaccine developed by The Serum Institute to prevent cervical cancer, was introduced last month. In a recent letter to the Health Ministry, Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII), stated that the company’s first indigenous HPV vaccination will be sold on the private market for Rs 2,000 per dose. CERVAVAC will be offered in glass vials with two doses.

IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details visit the link- https://irrespub.com/

Leave a Reply

Your email address will not be published. Required fields are marked *

error

Enjoy this blog? Please spread the word :)

WhatsApp
LinkedIn
Share
Follow by Email
RSS
Specialties in the marine industry :.